Clinical Trial Update: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing mirvetuximab soravtansine to investigator's choice chemotherapy in FR alpha-positive advanced epithelial ovarian, primary peritoneal, or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-06-09